“`html
Shares of Cidara Therapeutics Inc (Symbol: CDTX) rose to $75.47 on [insert date], exceeding the average analyst 12-month target price of $74.00. Analysts react to this crossing by either downgrading their valuations or raising their target prices based on business developments.
Currently, there are 6 analysts covering CDTX, with target prices ranging from $45.00 to $115.00, yielding a standard deviation of $22.81. The consensus among analysts is strong, with 5 “Strong Buy” ratings, 2 “Buy” ratings, and 1 “Hold” rating, resulting in an average rating of 1.5 on a scale where 1 is “Strong Buy” and 5 is “Strong Sell.”
“`
